Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASP 7962

Drug Profile

ASP 7962

Alternative Names: ASP7962

Latest Information Update: 07 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma Europe Ltd
  • Class Analgesics
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Feb 2018 Discontinued - Phase-II for Pain in Hungary, Czech Republic, Germany, Spain, United Kingdom and Belgium (PO) (Astellas Pharma pipeline, February 2018)
  • 27 Sep 2017 Astellas Pharma completes a phase I trial in Pain in Belgium, Czech Republic, Hungary, United Kingdom, Spain, Germany (PO) (NCT02611466)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top